Passive delivery of protein drugs through transdermal route

References

• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655–672.
   PubMed Web of Science ®Google Scholar
• Walter JR, Xu S. Therapeutic transdermal drug innovation from 2000 to 2014: current status and outlook. Drug Discov Today. 2015;20:1293–1299.
   PubMed Web of Science ®Google Scholar
• Watkinson AC, Kearney M-C, Quinn HL, et al. Future of the transdermal drug delivery market – have we barely touched the surface? Expert Opin Drug Deliv. 2016;13:523–532.
   PubMed Web of Science ®Google Scholar
• Wiedersberg S, Guy RH. Transdermal drug delivery: 30+ years of war and still fighting! J Control Release. 2014;190:150–156.
   PubMed Web of Science ®Google Scholar
• Kinch MS. An overview of FDA-approved biologics medicines. Drug Discov Today. 2015;20:393–398.
   PubMed Web of Science ®Google Scholar
• Katikaneni S. Transdermal delivery of biopharmaceuticals: dream or reality? Ther Deliv. 2015;6:1109–1116.
   PubMed Web of Science ®Google Scholar
• Kalluri H, Banga AK. Transdermal delivery of proteins. AAPS PharmSciTech. 2011;12:431–441.
   PubMed Web of Science ®Google Scholar
• Munch S, Wohlrab J, Neubert RHH. Dermal and transdermal delivery of pharmaceutically relevant macromolecules. Eur J Pharm Biopharm. 2017;119:235–242.
   PubMed Web of Science ®Google Scholar
• Wong TW, Nor Khaizan A. Physicochemical modulation of skin barrier by microwave for transdermal drug delivery. Pharm Res. 2013;30:90–103.
   PubMed Web of Science ®Google Scholar
• Herwadkar A, Banga A. Transdermal delivery of peptides and proteins. In: Van Der Walle C, editor. Peptide and protein delivery. Chap. 4. Amsterdam: Elsevier; 2011. p. 69–86.
   Google Scholar
• Perumal O, Murthy S, Kalia Y. Turning theory into practice: the development of modern transdermal drug delivery systems and future trends. Skin Pharmacol Physiol. 2013;26:331–342.
   PubMed Web of Science ®Google Scholar
• Bouwstra JA, Dubbelaar FE, Gooris GS, et al. The lipid organisation in the skin barrier. Acta Derm Venereol Suppl (Stockh). 2000;208:23–30.
   PubMedGoogle Scholar
• Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, et al. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res. 2003;42:1–36.
   PubMed Web of Science ®Google Scholar
• Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev. 2002;54(Suppl 1):S41–S55.
   PubMed Web of Science ®Google Scholar
• Boncheva M. The physical chemistry of the stratum corneum lipids. Int J Cosmet Sci. 2014;36:505–515.
   PubMed Web of Science ®Google Scholar
• Matsui T, Amagai M. Dissecting the formation, structure and barrier function of the stratum corneum. Int Immunol. 2015;27:269–280.
   PubMed Web of Science ®Google Scholar
• van Smeden J, Janssens M, Gooris GS, et al. The important role of stratum corneum lipids for the cutaneous barrier function. Biochim Biophys Acta. 2014;1841:295–313.
   PubMed Web of Science ®Google Scholar
• Madison KC. Barrier function of the skin: “la raison d'être” of the epidermis. J Invest Dermatol. 2003;121:231–241.
   PubMed Web of Science ®Google Scholar
• Barry BW. Action of skin penetration enhancers—the lipid protein partitioning theory. Int J Cosmet Sci. 1988;10:281–293.
   PubMed Web of Science ®Google Scholar
• Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–137.
   Web of Science ®Google Scholar
• Dragicevic N, Atkinson JP, Maibach HI. Chemical penetration enhancers: classification and mode of action. In: Dragicevic N, Maibach H, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement. Berlin, Heidelberg: Springer; 2015. p. 11–27.
   Google Scholar
• Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharm Res. 2009;8(2):173–179.
   Web of Science ®Google Scholar
• Klimentová J, Hrabálek A, Vávrová K, et al. Synthesis and transdermal penetration-enhancing activity of carbonic and carbamic acid esters—comparison with transkarbam 12. Bioorg Med Chem Lett. 2006;16:1981–1984.
   PubMed Web of Science ®Google Scholar
• Parhi R, Suresh P, Mondal S, et al. Novel penetration enhancers for skin applications: a review. CDD. 2012;9:219–230.
   PubMed Web of Science ®Google Scholar
• Bhatia KS, Singh J. Mechanism of transport enhancement of LHRH through porcine epidermis by terpenes and iontophoresis: permeability and lipid extraction studies. Pharm Res. 1998; 15:1857–1862.
   PubMed Web of Science ®Google Scholar
• Smyth HD, Becket G, Mehta S. Effect of permeation enhancer pretreatment on the iontophoresis of luteinizing hormone releasing hormone (LHRH) through human epidermal membrane (HEM). J Pharm Sci. 2002;91:1296–1307.
   PubMed Web of Science ®Google Scholar
• Moghadam SH, Saliaj E, Wettig SD, et al. Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm. 2013;10:2248–2260.
   PubMed Web of Science ®Google Scholar
• Bhatia KS, Gao S, Singh J. Effect of penetration enhancers and iontophoresis on the FT-IR spectroscopy and LHRH permeability through porcine skin. J Control Release. 1997;47:81–89.
   Web of Science ®Google Scholar
• Kumar S, Zakrewsky M, Chen M, et al. Peptides as skin penetration enhancers: mechanisms of action. J Control Release. 2015;199:168–178.
   PubMed Web of Science ®Google Scholar
• Namjoshi S, Benson HA. Cyclic peptides as potential therapeutic agents for skin disorders. Biopolymers. 2010;94:673–680.
   PubMed Web of Science ®Google Scholar
• Menegatti S, Zakrewsky M, Kumar S, et al. De novo design of skin-penetrating peptides for enhanced transdermal delivery of peptide drugs. Adv Healthcare Mater. 2016;5:602–609.
   Web of Science ®Google Scholar
• Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. 2009;157:195–206.
   PubMed Web of Science ®Google Scholar
• Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 2005;57:529–545.
   PubMed Web of Science ®Google Scholar
• Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med. 2012;18:385–393.
   PubMed Web of Science ®Google Scholar
• Chugh A, Eudes F, Shim YS. Cell-penetrating peptides: nanocarrier for macromolecule delivery in living cells. IUBMB Life. 2010;62:183–193.
   PubMed Web of Science ®Google Scholar
• Dupont E, Prochiantz A, Joliot A. Penetratin story: an overview. Methods Mol Biol. 2011;683:21–29.
   PubMedGoogle Scholar
• Lindgren M, Langel U. Classes and prediction of cell-penetrating peptides. Methods Mol Biol. 2011;683:3–19.
   PubMedGoogle Scholar
• Elmquist A, Hansen M, Langel U. Structure–activity relationship study of the cell-penetrating peptide pVEC. Biochim Biophys Acta. 2006;1758:721–729.
   PubMed Web of Science ®Google Scholar
• Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2001;276:5836–5840.
   PubMed Web of Science ®Google Scholar
• Morris MC, Deshayes S, Heitz F, et al. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell. 2008;100:201–217.
   PubMed Web of Science ®Google Scholar
• Pooga M, Hallbrink M, Zorko M, et al. Cell penetration by transportan. FASEB J. 1998;12:67–77.
   PubMed Web of Science ®Google Scholar
• Rousselle C, Smirnova M, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther. 2001;296:124–131.
   PubMed Web of Science ®Google Scholar
• Jain A, Shah SG, Chugh A. Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis. Pharm Res. 2015;32:1920–1930.
   PubMed Web of Science ®Google Scholar
• Cohen-Avrahami M, Shames AI, Ottaviani MF, et al. HIV-TAT enhances the transdermal delivery of NSAID drugs from liquid crystalline mesophases. J Phys Chem B. 2014;118:6277–6287.
   PubMed Web of Science ®Google Scholar
• Jin LH, Bahn JH, Eum WS, et al. Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. Free Radic Biol Med. 2001;31:1509–1519.
   PubMed Web of Science ®Google Scholar
• Hou L, Kong M. Enhanced transdermal lymphatic drug delivery of hyaluronic acid modified transfersome for tumor metastasis therapy. J Control Release. 2015;213:e77.
   PubMed Web of Science ®Google Scholar
• Nasrollahi SA, Taghibiglou C, Azizi E, et al. Cell-penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des. 2012;80:639–646.
   PubMed Web of Science ®Google Scholar
• Gennari CG, FranzeÌ S, Pellegrino S, et al. Skin penetrating peptide as a tool to enhance the permeation of heparin through human epidermis. Biomacromolecules. 2015;17:46–55.
   PubMed Web of Science ®Google Scholar
• de Cogan F, Hill LJ, Lynch A, et al. Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides CPP delivery of anti-VEGF drugs to the retina. Invest Ophthalmol Vis Sci. 2017;58:2578–2590.
   PubMed Web of Science ®Google Scholar
• Shi N-Q, Qi X-R, Xiang B, et al. A survey on “Trojan Horse” peptides: opportunities, issues and controlled entry to “Troy”. J Control Release. 2014;194:53–70.
   PubMed Web of Science ®Google Scholar
• Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol. 2010;27:247–259.
   PubMed Web of Science ®Google Scholar
• Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem. 2003;278:585–590.
   PubMed Web of Science ®Google Scholar
• Di Pisa M, Chassaing G, Swiecicki J-M. Translocation mechanism(s) of cell-penetrating peptides: biophysical studies using artificial membrane bilayers. Biochemistry. 2014;54:194–207.
   PubMed Web of Science ®Google Scholar
• Kumar S, Narishetty ST, Tummala H. Peptides as skin penetration enhancers for low molecular weight drugs and macromolecules. In: Dragicevic N, Maibach H, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement. Berlin, Heidelberg: Springer; 2015. p. 337–352.
   Google Scholar
• Hsu T, Mitragotri S. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci. 2011;108:15816–15821.
   PubMed Web of Science ®Google Scholar
• Chen M, Gupta V, Anselmo AC, et al. Topical delivery of hyaluronic acid into skin using SPACE-peptide carriers. J Control Release. 2014;173:67–74.
   PubMed Web of Science ®Google Scholar
• Chen M, Kumar S, Anselmo AC, et al. Topical delivery of cyclosporine A into the skin using SPACE-peptide. J Control Release. 2015;199:190–197.
   PubMed Web of Science ®Google Scholar
• Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA. 1987;84:5449–5453.
   PubMed Web of Science ®Google Scholar
• Kim YC, Ludovice PJ, Prausnitz MR. Transdermal delivery enhanced by magainin pore-forming peptide. J Control Release. 2007;122:375–383.
   PubMed Web of Science ®Google Scholar
• Kim Y-C, Ludovice PJ, Prausnitz MR. Optimization of transdermal delivery using magainin pore-forming peptide. J Phys Chem Solids. 2008;69:1560–1563.
   PubMed Web of Science ®Google Scholar
• Kim YC, Late S, Banga AK, et al. Biochemical enhancement of transdermal delivery with magainin peptide: modification of electrostatic interactions by changing pH. Int J Pharm. 2008;362:20–28.
   PubMed Web of Science ®Google Scholar
• Chen Y, Shen Y, Guo X, et al. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol. 2006;24:455–460.
   PubMed Web of Science ®Google Scholar
• Lopes LB, Carvalho V, de Lemos DP. Potential of peptide-based enhancers for transdermal delivery. CPD. 2015;21:2814–2822.
   Web of Science ®Google Scholar
• Kristensen M, Birch D, Mørck Nielsen H. Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. IJMS. 2016;17:185.
   Web of Science ®Google Scholar
• Touitou E. Drug delivery across the skin. Expert Opin Biol Ther. 2002;2:723–733.
   PubMed Web of Science ®Google Scholar
• Mezei M, Gulasekharam V. Liposomes—a selective drug delivery system for the topical route of administration: lotion dosage form. Life Sci. 1980;26:1473–1477.
   PubMed Web of Science ®Google Scholar
• Ganesan MG, Weiner ND, Flynn GL, et al. Influence of liposomal drug entrapment on percutaneous absorption. Int J Pharm. 1984;20:139–154.
   Web of Science ®Google Scholar
• Konno T. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. IV: study on reduced-pressure mixing for practical use of amorphous mixtures of flufenamic acid. Chem Pharm Bull. 1990;38:2003–2007.
   PubMed Web of Science ®Google Scholar
• Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol. 2005;2:67–74.
   PubMedGoogle Scholar
• Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta (BBA)-Biomembr. 1992;1104:226–232.
   PubMed Web of Science ®Google Scholar
• Elsayed MM, Abdallah OY, Naggar VF, et al. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm. 2007;332:1–16.
   PubMed Web of Science ®Google Scholar
• Ahad A, Al-Saleh AA, Al-Mohizea AM, et al. Formulation and characterization of Phospholipon® 90 G and Tween® 80 based transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol. Forthcoming. [27 p.]. DOI: https://doi.org/10.1080/10837450.2017.1330345.
   Google Scholar
• Abdellatif AA, Tawfeek HM. Transfersomal nanoparticles for enhanced transdermal delivery of clindamycin. AAPS PharmSciTech. 2016;17:1067–1074.
   PubMed Web of Science ®Google Scholar
• Shreya AB, Managuli RS, Menon J, et al. Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. J Liposome Res. 2016; 26:221–232.
   PubMed Web of Science ®Google Scholar
• Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, transfersomes. Biochim Biophys Acta. 2001; 1514:191–205.
   PubMed Web of Science ®Google Scholar
• Guo J, Ping Q, Sun G, et al. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm. 2000;194:201–207.
   PubMed Web of Science ®Google Scholar
• Jain S, Sapre R, Tiwary AK, et al. Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation. AAPS PharmSciTech. 2005;6:E513–E522.
   PubMed Web of Science ®Google Scholar
• Cevc G, Gebauer D, Stieber J, et al. Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta (BBA)-Biomembr. 1998; 1368:201–215.
   PubMed Web of Science ®Google Scholar
• Song YK, Kim CK. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials. 2006;27:271–280.
   PubMed Web of Science ®Google Scholar
• Paul A, Cevc G, Bachhawat BK. Transdermal immunization with large proteins by means of ultradeformable drug carriers. Eur J Immunol. 1995;25:3521–3524.
   PubMed Web of Science ®Google Scholar
• Cevc G, Chopra A. Deformable (Transfersome®) vesicles for improved drug delivery into and through the skin. In: Dragicevic N, Maibach H, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement. Berlin, Heidelberg: Springer; 2016. p. 39–59.
   Google Scholar
• Murdan S. Organogels in drug delivery. Expert Opin Drug Deliv. 2005;2:489–505.
   PubMedGoogle Scholar
• Russell-Jones G, Himes R. Water-in-oil microemulsions for effective transdermal delivery of proteins. Expert Opin Drug Deliv. 2011;8:537–546.
   PubMed Web of Science ®Google Scholar
• Witting M, Obst K, Friess W, et al. Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers. Biotechnol Adv. 2015;33:1355–1369.
   PubMed Web of Science ®Google Scholar
• Getie M, Wohlrab J, Neubert RH. Dermal delivery of desmopressin acetate using colloidal carrier systems. J Pharm Pharmacol. 2005;57:423–427.
   PubMed Web of Science ®Google Scholar
• Himes R, Lee S, McMenigall K, et al. Reduction in inflammation in the footpad of carrageenan treated mice following the topical administration of anti-TNF molecules formulated in a micro-emulsion. J Control Release. 2010;145:210–213.
   PubMed Web of Science ®Google Scholar
• Goebel A, Schmaus G, Neubert R, et al. Dermal peptide delivery using enhancer molecules and colloidal carrier systems—Part I: carnosine. Skin Pharmacol Physiol. 2012;25:281–287.
   PubMed Web of Science ®Google Scholar
• Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev. 2002;54(Suppl 1):S77–S98.
   PubMed Web of Science ®Google Scholar
• Dreher F, Walde P, Walther P, et al. Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J Control Release. 1997;45:131–140.
   Web of Science ®Google Scholar
• Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63:470–491.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yu F, Park YS, et al. Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials. 2010;31:9086–9091.
   PubMed Web of Science ®Google Scholar
• Baroli B, Ennas MG, Loffredo F, et al. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol. 2007;127:1701–1712.
   PubMed Web of Science ®Google Scholar
• Chu M, Wu Q, Wang J, et al. In vitro and in vivo transdermal delivery capacity of quantum dots through mouse skin. Nanotechnology. 2007;18:455103.
   Web of Science ®Google Scholar
• Verma A, Jain A, Hurkat P, et al. Transfollicular drug delivery: current perspectives. Res Rep Transderm Drug Deliv. 2016;5:1–17.
   Google Scholar
• Kumar R, Katare OP. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review. AAPS PharmSciTech. 2005;6:E298–E310.
   PubMed Web of Science ®Google Scholar
• Almeida H, Amaral MH, Lobão P, et al. Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): main features and their applications in topical and transdermal administration of drugs. J Pharm Pharm Sci. 2012;15:592–605.
   PubMed Web of Science ®Google Scholar
• Murashova N, Yurtov E. Lecithin organogels as prospective functional nanomaterial. Nanotechnol Russia. 2015;10:511–522.
   Web of Science ®Google Scholar
• Witting M, Boreham A, Brodwolf R, et al. Interactions of hyaluronic acid with the skin and implications for the dermal delivery of biomacromolecules. Mol Pharm. 2015;12:1391–1401.
   PubMed Web of Science ®Google Scholar
• Essendoubi M, Gobinet C, Reynaud R, et al. Human skin penetration of hyaluronic acid of different molecular weights as probed by Raman spectroscopy. Skin Res Technol. 2016;22:55–62.
   PubMed Web of Science ®Google Scholar
• Brown MB, Jones SA. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venerol. 2005;19:308–318.
   PubMed Web of Science ®Google Scholar
• Yang JA, Kim ES, Kwon JH, et al. Transdermal delivery of hyaluronic acid – human growth hormone conjugate. Biomaterials. 2012;33:5947–5954.
   PubMed Web of Science ®Google Scholar
• Martins M, Azoia NG, Shimanovich U, et al. Design of novel BSA/hyaluronic acid nanodispersions for transdermal pharma purposes. Mol Pharm. 2014;11:1479–1488.
   PubMed Web of Science ®Google Scholar
• Dragicevic N, Maibach HI. Modification of the stratum corneum. In: Percutaneous penetration enhancers chemical methods in penetration enhancement. Berlin, Heidelberg: Springer; 2015.
   Google Scholar
• Bourguignon LY, Singleton PA, Diedrich F. Hyaluronan-CD44 interaction with Rac1-dependent protein kinase N-γ promotes phospholipase Cγ1 activation, Ca2+ signaling, and cortactin-cytoskeleton function leading to keratinocyte adhesion and differentiation. J Biol Chem. 2004;279:29654–29669.
   PubMed Web of Science ®Google Scholar
• Bundgaard H. (C) Means to enhance penetration: (1) prodrugs as a means to improve the delivery of peptide drugs. Adv Drug Deliv Rev. 1992;8:1–38.
   Web of Science ®Google Scholar
• Oliyai R, Stella VJ. Prodrugs of peptides and proteins for improved formulation and delivery. Annu Rev Pharmacol Toxicol. 1993;33:521–544.
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Lewis GP. Comparison of ampicillin and hetacillin pharmacokinetics in man. J Pharm Sci. 1973;62:69–76.
   PubMed Web of Science ®Google Scholar
• van Deurs B, Hansen SH, Olsnes S, et al. Protein uptake and cytoplasmic access in animal cells. In: Audus KL, Raub TJ, editors. Biological barriers to protein delivery. Boston (MA): Springer US; 1993. p. 71–104.
   Google Scholar
• Osborne DW. Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products. J Cosmet Dermatol. 2011;10:324–329.
   PubMed Web of Science ®Google Scholar
• Mura P, Faucci M, Bramanti G, et al. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci. 2000;9:365–372.
   PubMed Web of Science ®Google Scholar
• Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm. 2008;364:227–236.
   PubMed Web of Science ®Google Scholar
• Bashyal S, Lee S. Delivery of biopharmaceuticals using combination of liposome and iontophoresis: a review. J Pharm Investig. 2015;45:611–624.
   Google Scholar
• Wang Y, Thakur R, Fan Q, et al. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm. 2005;60:179–191.
   PubMed Web of Science ®Google Scholar
• Vemulapalli V, Yang Y, Friden PM, et al. Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J Pharm Pharmacol. 2008;60:27–33.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Mitragotri S, Patel A, et al. Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug delivery. J Pharm Sci. 1996;85:670–679.
   PubMed Web of Science ®Google Scholar
• Jain A, Tiwari A, Verma A, et al. Ultrasound-based triggered drug delivery to tumors. Drug Deliv Transl Res. 2018;8:150–164.
   PubMed Web of Science ®Google Scholar
• Le L, Kost J, Mitragotri S. Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery. Pharm Res. 2000;17:1151–1154.
   PubMed Web of Science ®Google Scholar